10-Q: BioNexus Gene Lab Corp. Reports Q2 2026 Results Amidst Revenue Decline

BioNexus Gene Lab Corp. filed its Q2 2026 report, detailing a substantial decrease in revenue and continued operational losses, while also addressing internal control deficiencies and strategic initiatives.

Summary

• BioNexus Gene Lab Corp. reported a significant decline in revenue for the three and six months ended June 30, 2026, compared to the prior year.
• The company experienced substantial net losses in both periods, with a loss of $286,451 for the three-month period and $830,026 for the six-month period.
• A material weakness in internal controls over financial reporting was identified, primarily related to the Chemrex subsidiary, with remediation efforts ongoing.
• Strategic initiatives include the continued development of the VitaGuard MRD platform and modernization of the BGS platform, though VitaGuard has not yet generated revenue.
• The company's liquidity position is supported by cash and cash equivalents of $2,391,945 as of June 30, 2026, with management believing it is sufficient for at least the next 12 months.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant revenue declines, ongoing losses, and material weaknesses in internal controls, despite some strategic advancements.

Positives

• The company has a cash and cash equivalents balance of $2,391,945 as of June 30, 2026, which management believes is sufficient for at least the next 12 months.
• Gross margin for Chemrex improved to 17.10% in Q2 2026 from 16.27% in Q2 2025.
• Research and development costs increased slightly, indicating continued investment in the BGS test.
• The company is actively pursuing strategic partnerships and evaluating opportunities for growth.
• The CEO and President, Su-Leng Tan Lee, has had his employment agreement renewed for a three-year fixed term.
• The company is exploring a new business model for Chemrex, including expanding into different chemical types and the CDMO business.

Negatives

• Revenue decreased by 96.63% for the three-month period ended June 30, 2026, compared to the prior year.
• Revenue decreased by 97.75% for the six-month period ended June 30, 2026, compared to the prior year.
• The company incurred net losses of $286,451 and $830,026 for the three- and six-month periods ended June 30, 2026, respectively.
• A material weakness in internal controls over financial reporting was identified at the Chemrex subsidiary.
• The VitaGuard MRD platform has not yet generated any revenue for the company as of June 30, 2026.
• The company's independent auditors expressed concerns regarding certain aspects of Chemrex's financial reporting and internal control structure.
• The company is facing legal proceedings related to alleged unauthorized payments at its Chemrex subsidiary.

Risks

• The commercialization of VitaGuard depends on the completion of post-closing verification, perfection, and implementation work, as well as regulatory and operational readiness, and revenue may not be generated.
• Errors or omissions in transaction schedules, inaccuracies in representations and warranties, deficiencies in supporting documentation, or disagreements regarding contractual obligations could delay regulatory preparation, validation, laboratory readiness, or commercial launch.
• The company has identified material weaknesses in internal controls over financial reporting at its Chemrex subsidiary, and remediation is ongoing.
• The company's ability to continue as a going concern is dependent on improving operating results and maintaining adequate liquidity, with substantial doubt raised by current financial conditions.
• If the company obtains debt financing, it may be subject to restrictive covenants and repayment obligations that could adversely affect its operations.
• If the company raises capital through the issuance of equity securities, existing stockholders may experience substantial dilution.

Future Outlook

The company is focused on modernizing its BGS platform and advancing VitaGuard commercialization. Management believes current cash and expected financing under the ATM Program are sufficient for at least the next 12 months. Future compliance with Nasdaq listing standards will depend on continued satisfaction of quantitative and qualitative requirements.

Management Comments

• Management believes that the Company's existing cash balance, together with its positive working capital position, will provide sufficient liquidity to fund operations and meet its obligations as they become due for at least the next twelve months.
• The Company continues to evaluate capital-raising alternatives, which may include at-the-market offerings, private placements or strategic financing arrangements, subject to market conditions, corporate authorization, Nasdaq and SEC requirements and the Company's capital needs.
• Management remains focused on rebuilding customer activity, maintaining collection discipline, strengthening credit controls and completing inventory verification for Chemrex.
• The Company is addressing concerns raised by its independent auditors regarding Chemrex's financial reporting and internal control structure through comprehensive oversight.

Industry Context

StockSavvy.ai notes that BioNexus Gene Lab Corp. operates in the diagnostics and specialty chemicals sectors. The significant revenue decline in both segments, particularly in industrial chemicals, suggests broader market pressures or company-specific challenges. The focus on advancing the VitaGuard MRD platform aligns with industry trends towards precision medicine and early disease detection, but its revenue generation is still pending.

Comparison to Industry Standards

• The substantial revenue decline of over 96% for both the three and six-month periods ending June 30, 2026, is significantly worse than typical performance for companies in the diagnostics and specialty chemicals sectors, which often aim for steady growth or at least stable revenues.
• The company's net loss of $830,026 for the six-month period, while reduced from the prior year, indicates a continued struggle for profitability, which is a key benchmark for established companies in these industries.
• The identified material weakness in internal controls at the Chemrex subsidiary is a significant concern, as robust internal controls are a fundamental expectation for publicly traded companies, especially those operating in regulated industries like diagnostics.
• The company's reliance on future financing and the ongoing need to raise capital are common for early-stage or turnaround companies but contrast with the more stable financial profiles of larger, established players in the diagnostics and chemical sectors.

Management Changes

Corporate Governance

Legal Proceedings

• The Company issued Letters of Demand to five former officers and directors of Chemrex demanding repayment of approximately $2,944,000 for alleged unauthorized payments made between July 2024 and August 2025.
• The Company continues to investigate the activities of these parties and their effect on Chemrex, intending to pursue available claims and remedies.

Related Party Transactions

• The company reported $nil revenue from related parties for the three-month period ended June 30, 2026, and $32,179 for the six-month period ended June 30, 2025.
• Other payables and accrued liabilities included $296,331 from related parties as of June 30, 2026, compared to $83,333 as of December 31, 2025.
• The related-party payable of $296,331 as of June 30, 2026, relates to amounts due to Fidelion under the License Agreement.

Stakeholder Impact

• Shareholders may experience substantial dilution if the company raises capital through equity issuance.
• The material weakness in internal controls could impact investor confidence and the reliability of financial reporting.
• The significant revenue decline and ongoing losses may affect the company's ability to fund future growth and operations, potentially impacting long-term shareholder value.
• The legal proceedings against former Chemrex officers and directors could lead to recovery of funds, benefiting the company and its shareholders, but also involve potential costs and uncertainties.

Next Steps

• Continue modernizing and rebuilding the blood-based genomic screening (BGS) platform through GeneMatrix Systems.
• Advance VitaGuard commercialization planning and implementation in ASEAN.
• Stabilize Chemrex's core trading operations and collections, and explore CDMO opportunities.
• Continue evaluating strategic partnerships and transactions, including potential mergers, acquisitions, and joint ventures.
• Develop an updated corporate website and presentation materials for release in Q3 2026.
• Continue implementing and testing remediation measures for internal controls.

Key Dates

Recommendation

The significant revenue decline, persistent net losses, material weakness in internal controls, and ongoing legal proceedings present substantial risks. While strategic initiatives are underway, their success and ability to generate revenue are uncertain. The company's reliance on future capital raises also poses dilution risks. These factors collectively suggest a negative outlook for the stock in the near to medium term.

Keywords

BioNexus Gene Lab Corp, Form 10-Q, Quarterly Report, Genomic Screening, Industrial Chemicals, VitaGuard, MRD, Fidelion Diagnostics